Douglas Drager

发表

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice

R. Blumberg, D. Lillicrap, N. Josephson, 2015, Cellular immunology.

Phagocytosis-shielded lentiviral vectors improve liver gene therapy in nonhuman primates

A. Annoni, M. Biffi, L. Naldini, 2019, Science Translational Medicine.

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020 .

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates

A. Annoni, M. Biffi, C. Brombin, 2021, Nature Communications.

Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

Amy M. Holthaus, V. Schellenberger, J. Kulman, 2015 .

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs.

A. Bitonti, J. Dumont, T. Nichols, 2012, Blood.

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes

Haiyan Jiang, D. Light, A. van der Flier, 2015, PloS one.

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Terrence M. Dobrowsky, Amy M. Holthaus, J. Sommer, 2020, Blood.

Different Contribution of Hematopoietic and Somatic Cell Types Expressing FcRn to the Prolonged Half-Life of Recombinant Factor VIII Fc and Recombinant FIX Fc

Haiyan Jiang, K. Wharton, D. Light, 2012 .